Sanhuang Jinhua Powder Veterinary Grade API is a multi-component botanical active pharmaceutical ingredient supplied for further manufacture of veterinary tablets, injections, capsules, powders, granules, premixes, and solutions. The material is produced from a declared mixture of botanical source materials by aqueous or hydroalcoholic extraction, followed by clarification, concentration, drying, and controlled milling. Because the powdered extract is not a finished dosage form, its use is governed by a veterinary drug dossier that defines the product-specific specification, manufacturing process, and stability profile.

No harmonized international model code uniquely identifies this named API. The manufacturer’s batch designation and product code typically encode the drying route, milling target, and packaging line; therefore, a batch identifier alone does not establish interchangeability between tablet-grade and injection-grade material. Purchasers should verify the certificate of analysis for each lot against the specification approved for the intended dosage form. A model identifier may indicate spray-dried powder with a target particle size expressed as D90, or vacuum-dried powder intended for subsequent micronization before liquid formulation.

The API is commonly supplied as a fine, hygroscopic powder with particle size distribution measured by laser diffraction and reported as D10, D50, and D90 in µm. The powder may contain soluble and insoluble botanical components, including flavonoids and alkaloids. This compositional complexity creates different processing risks in tablets, injections, capsules, powders, granules, premixes, and solutions. The following sections identify those risks and the corresponding control points.

Specification controls for botanical marker content and residual solvent profile

The release specification should be established from three or more production-scale batches and should include identification, assay, moisture, ash, heavy metals, microbial quality, residual solvents, and particle size. Identification by thin-layer chromatography or high-performance liquid chromatography should compare retention times and peak areas against a qualified reference extract. Because the product is multi-component, a single marker is rarely sufficient to control lot-to-lot consistency; a combined marker approach may be required when the target species require a defined range of total flavonoids, alkaloids, or extractable solids.

Residual moisture is a critical control point because the dried extract can reabsorb water during storage and handling. If the loss on drying exceeds the approved limit, fluid-bed or vacuum drying is applied before further processing. Over-drying can embrittle the powder and generate electrostatic charges that reduce blend uniformity. The particle size specification should therefore be connected to the intended manufacturing route: a finer D90 may improve suspensibility in solutions, while a coarser D50 may improve flow in tablet or capsule filling.

Microbial enumeration is determined by membrane filtration or plate count methods suitable for non-sterile botanical APIs. For powder intended for oral solid dosage forms, the critical acceptance criterion is typically total aerobic microbial count, total yeast and mold count, and absence of specified pathogens. For powders that may be further processed into injectable solutions, bioburden and bacterial endotoxin controls must be tightened because terminal manufacture may not include a kill step. Pesticide residue testing should be considered when the botanical source is not obtained from controlled cultivation; the analytical method may use gas or liquid chromatography coupled with mass spectrometry. Heavy metals are controlled by inductively coupled plasma mass spectrometry because certain botanical matrices can accumulate lead, cadmium, arsenic, and mercury. A quality system certified under ISO 9001 or an equivalent veterinary GMP scheme is not sufficient to release a batch; the certificate of analysis must show lot-specific results for the critical parameters.

For tablet and capsule manufacture, the API is commonly granulated rather than directly compressed. The powder may exhibit poor flow and high cohesiveness because of residual moisture and particle surface energy. In a high-shear granulator with impeller torque monitoring, water or a binder solution is added until the wet mass reaches a defined torque endpoint. The endpoint is not fixed solely by added quantity; batch-to-batch variation in botanical extract solubility requires power-consumption feedback. The wet granules are dried in a fluid-bed dryer with inlet air temperature generally not exceeding 60 °C, because higher temperatures can darken the extract and reduce marker content. Drying is continued until the loss on drying falls within the approved range for tablet compression.

Direct compression of this API is operationally feasible only after dry granulation or with flow aids, but tablet weight variation risk increases when the angle of repose exceeds 40° or the Carr index exceeds 25%. Powder flow evaluation may be performed according to USP <1174>. Roller compaction followed by milling can produce dense granules with improved bulk density and reduced dust, but overcompaction may reduce tablet tensile strength and slow disintegration. During tablet compression, the granule blend is loaded into a rotary tablet press with forced feeder. Ejection force and pre-compression force should be recorded to detect variation caused by residual moisture or granule hardness. If ejection force increases with punch temperature, lubrication level and punch coating should be evaluated. Capsule filling using a dosator or tamping-style machine requires the powder to have stable bulk density; otherwise fill weight variation can increase when hopper fill depth changes. Automated weight control systems on continuous capsule fillers may mask small stick-slip fluctuations, but the coefficient of variation of filled weight should be monitored at start, middle, and end of the run.

What distinguishes an injectable-grade powder from the same API in oral-dosage processing?

Injectable products impose requirements that are not inherent to oral solid dosage forms. The dry powder may be acceptable for tablet manufacturing while remaining unsuitable for parenteral administration because of bacterial endotoxin load, insoluble particulate matter, and potential pyrogen content. For injection or solution for infusion, the API must undergo additional dissolution, clarification, depyrogenation, and sterilizing filtration. The acceptance limit for bacterial endotoxins is derived from the maximum dose and the target species; the compendial test may be conducted by limulus amebocyte lysate assay according to Ph. Eur. 2.6.14 or an equivalent veterinary pharmacopoeial chapter. Endotoxin control is not a routine release parameter for coated tablets unless the marketing authorization explicitly requires it.

Particulate matter in injectable solutions is controlled by light obscuration and microscopic count methods such as USP <788>. After reconstitution or dilution, the solution should be passed through a 0.22 µm sterilizing-grade membrane filter. Prefiltration through a depth filter or 0.45 µm clarification membrane is often required because the botanical matrix contains colloidal and fibrous particles that can block the sterilizing-grade membrane and reduce flux. Filter compatibility testing should cover extractable and leachable species, particularly when the solution contains co-solvents such as ethanol or propylene glycol.

The alkaloid fraction of the extract may precipitate when the pH is raised above approximately 8.0. Acidic conditions may also degrade certain flavonoid glycosides or cause color changes that complicate photometric assay. Injection development should include pH stability studies across the intended buffer range, and the final formulation should be protected from light when forced-degradation data show photodegradation. Published product-specific kinetic data for this named botanical API are limited; each formulation must be qualified with worst-case processing trials.

Terminal sterilization at 121 °C may be evaluated only after confirming assay retention and degradation product formation. If the injection is processed aseptically, the holding time between dissolution and filtration should be minimized to limit microbial proliferation and hydrolysis. The product is not intrinsically sterile, and sterility assurance resides in the downstream process, not in the API itself.

When the API is dispersed into liquid premix rather than compressed into a tablet

Liquid premixes and oral solutions present different suspending and dissolution challenges. The powder should be screened through an inline sieve or security screen before wetting to reduce agglomerates. For aqueous premixes, adding the powder to a well-mixed vessel equipped with a high-shear rotor-stator mixer can reduce hydration time, but fine botanical particles may foam at high speed. Mixing speed should be selected according to vessel geometry and product viscosity, with visual and viscosity checks at defined intervals. If the premix is intended for automatic drinking lines, the final suspension must pass through the target nipple or proportioner without clogging and should remain redispersible after standing for the specified contact time.

Solubility is not uniform; the product generally forms a suspension rather than a true solution unless further clarification and separation are performed. pH adjustment can improve the solubility of some alkaloid constituents but may reduce the solubility of other components. The use of co-solvents, preservatives, or stabilizers requires compatibility screening because botanical extracts contain polyphenols that may complex with certain synthetic preservatives. Suspension stabilizers such as xanthan gum or co-processed microcrystalline cellulose may be evaluated by rotational rheometry to ensure that thixotropic settling remains acceptable after 24 h. In the absence of product-specific stability data, liquid premix batches should be prepared close to the point of use and should be protected from prolonged storage above 25 °C.

The principal difference between this veterinary-grade API and feed-grade botanical powders is the control of pharmaceutical impurities, microbial attributes, and manufacturing traceability. Feed-grade powders may contain carriers, drying aids, or non-declared botanical fractions that are not suitable for parenteral or tablet manufacture. Veterinary API material is manufactured under veterinary GMP and is tested for heavy metals, residual solvents, pesticide residues where applicable, and microbial limits appropriate to the intended route of administration. Feed-grade material may not carry a chromatographic fingerprint or marker assay, making dose uniformity and batch-to-batch consistency less reliable for pharmaceutical compounding.

Compared with single-compound APIs, the product has a wider chromatographic profile and a higher propensity for extract-specific processing interactions. The presence of multiple chemical families can affect moisture sorption, tablet hardening, and solution stability. This does not preclude robust manufacture, but it requires that formulation studies use the same specification grade intended for commercial production. Substitution of an unqualified lot or a lower-grade powder from another supplier is a major source of batch failure in wet granulation and injectable solution preparation.

Operationally, the powder should be stored in tightly closed packaging below 25 °C and protected from moisture, direct light, and strong oxidizing agents. When relative humidity exceeds 60%, pre-drying may be required before tableting or encapsulation. Incompatible mixing with strong alkaline solutions may precipitate alkaloid components; combining the powder with strong oxidizers may degrade color and marker compounds. Each production site should qualify the specific package configuration, warehouse storage period, and transfer procedure before routine use.